NCT03938545: A trial that was reported late by Immunovant Sciences GmbH
This trial has reported, although it was 181 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03938545 |
|---|---|
| Title | ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 23, 2019 |
| Completion date | Feb. 2, 2021 |
| Required reporting date | Feb. 2, 2022, midnight |
| Actual reporting date | Aug. 2, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 181 |